Inactive Instrument

Weifa ASA

WEIFA

NO0010308240

Olav Hellebø to Leave Clavis Pharma as MDD

May 14, 2013 at 03:59 pm

Clavis Pharma's MD Olav Hellebø is leaving the company. This the result of ongoing downscaling in the company following the failed test results for a cancer medication that has been under development.

Latest news about Weifa ASA

Weifa ASA Announces Board Appointments	17/10/17	CI
Karo Pharma AB (OM:KARO) completed the acquisition of Weifa ASA (OB:WEIFA) from Holta Life Sciences AS, Watrium AS and others.	05/10/17	CI
An unknown buyer acquired 9.1% stake in Weifa ASA (OB:WEIFA) from MVN Event Driven Master Fund Limited fund managed by MVN Asset Management Limited and MVN Asset Management Limited.	25/09/17	CI
Weifa ASA(OB:WEIFA) dropped from S&P Global BMI Index	18/09/17	CI
Karo Pharma AB (OM:KARO) entered into a transaction agreement to make an offer to acquire Weifa ASA (OB:WEIFA) from Holta Life Sciences AS, Watrium AS and others for NOK 1.3 billion.	23/08/17	CI
Weifa ASA Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017; Provides Earnings Guidance for the Year 2017	13/07/17	CI
Weifa ASA Announces Dividend, Payable on June 8, 2017	30/05/17	CI
Weifa ASA Announces Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2016	28/04/17	CI
The mutual funds managed by Nordea Funds Oy acquired an additional 0.54% stake in Weifa ASA (OB: WEIFA).	19/03/17	CI
Weifa ASA Proposes Dividend for the Fourth Quarter of 2016, Payable on June 8, 2017	16/02/17	CI
Weifa ASA Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016	16/02/17	CI
Weifa Announces New License Agreement with AFT Pharmaceuticals for Nordic Rights to Groundbreaking Product Line Within Pain Management	12/01/17	CI
Weifa ASA Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016; Provides Earnings Guidance for 2016	25/10/16	CI
Weifa ASA to Launch Lbux(R) 200 mg Soft Capsules to Strengthen its Pain Relief Portfolio	11/10/16	CI
Weifa ASA Launches Solvivo(R) Lozenges	14/09/16	CI
Weifa ASA Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016; Provides Earnings Guidance for Full Year of 2016	25/08/16	CI
Weifa ASA Announces the Launch of Zonat Tablets	10/08/16	CI
Weifa ASA (OB:WEIFA) announces an Equity Buyback for 20,000 shares, for NOK 0.02 million.	06/07/16	CI
Tranche Update on Weifa ASA (OB:WEIFA)'s Equity Buyback Plan announced on July 6, 2016.	06/07/16	CI
Weifa ASA authorizes a Buyback Plan.	05/07/16	CI
Weifa ASA's Equity Buyback announced on July 6,2016 has closed with 20,000 shares for NOK 0.02 million.	05/07/16	CI
Weifa ASA Signs Distribution Agreement with Fysioline Group	06/06/16	CI
Weifa ASA Declares Dividend, Payable on June 10, 2016	01/06/16	CI
Weifa ASA Proposes Dividend for First Quarter of 2016; Reports Earnings Results for the First Quarter of 2016; Announces Future Product Launches; Provides Earnings Guidance for the Year 2016	26/04/16	CI
Weifa ASA Secures New Loan Agreement with DNB	21/03/16	CI

Chart Weifa ASA

Duration

Period

More charts

Company Profile

Sector

Pharmaceuticals

More about the company

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
SUN PHARMACEUTICAL INDUSTRIES LTD.	+25.40%	45.54B
OTSUKA HOLDINGS CO., LTD.	+34.52%	24.51B
SANDOZ GROUP AG	+27.12%	16.48B
CIPLA LIMITED	+21.19%	14.66B
ZYDUS LIFESCIENCES LIMITED	+71.91%	14.3B
THE MEDICINES COMPANY	-0.05%	6.79B
ONO PHARMACEUTICAL CO., LTD.	-11.84%	6.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+18.15%	5.87B
STADA ARZNEIMITTEL	-8.87%	5.73B

Generic Pharmaceuticals